Document is current
Any future updates will be listed below
-
Authors
Celichowski, Piotr
Turi, Marcello
Charvátová, Sandra
Radhakrishnan, Dhwani
Feizi, Neda
Chyra, Zuzana
Šimíček, Michal
Jelínek, Tomáš
Bago, Juli Rodriguez
Hájek, Roman
Hrdinka, Matouš https://orcid.org/0000-0002-2981-2825
-
Funding
Funding for this research was provided by:
Ministerstvo Zdravotnictví Ceské Republiky (MH CZ-DRO-FNOs/2022, NU21-03-00032)
ERDF - Cell Coolab Ostrava—Research and Development Center for Cell Therapy in Hematology and Oncology (CZ.02.1.01/0.0/0.0/17_049/0008440)
Interní grantová soutěž pro studenty doktorského studia na Ostravské univerzitě (CZ.02.2.69/0.0/0.0/19_073/0016939)
- License Information
-
More Information
Article History
Received: 8 February 2023
Accepted: 7 March 2023
First Online: 15 March 2023
Declarations
:
: Not applicable.
: Not applicable.
: T.J. received honoraria from Amgen, BMS, Janssen, GSK, Takeda, Pfizer, Sanofi; and research funding from Sanofi, Janssen, Amgen. R.H. has had a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar, and Takeda; has received honoraria from Janssen, Amgen, Celgene, BMS, PharmaMar, and Takeda; has received research funding from Janssen, Amgen, Celgene, BMS, Novartis, and Takeda. All other authors declare no competing interests.
